Catalyst Wire Dossier Catalyst Wire Dossier

Netarsudil 0.02% / Latanoprost 0.005% fixed-dose combination

Netarsudil/latanoprost fixed-dose combination
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Netarsudil 0.02% / Latanoprost 0.005% fixed-dose combination, covering 2025-11-18 to 2025-11-18. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma [Phase 4]

See pricing